Achieving Equitable Access to CAR-T & Other Cellular Therapy Through RNA Engineering

Time: 4:50 pm
day: Day Two


  • Use of DNA-based cell therapy approaches is limited to academic medical centers in high-income countries due to high costs of manufacturing as well as the level of clinical care needed to manage toxicities
  • RNA-engineered cellular therapy is less expensive to manufacture, less complex to prepare and administer and has less potential for significant short and long-term toxicity
  • Cartesian Therapeutics has successfully used three different mRNA-engineered cell therapy products in community clinics around the US, as well as in academic centers in a low/medium-income country, demonstrating the potential of RNA to make global distribution of effective clinical therapies more equitable